1 / 1
High-Quality Triptorelin CAS：57773-63-4 Quotes, Service
Product Description
Triptorelin is a synthetic decapeptide gonadotropin-releasing hormone (GnRH) agonist that works by acting continuously on pituitary GnRH receptors, initially stimulating and ultimately inhibiting the secretion of gonadotropins (LH, FSH), thereby reducing sex hormone (testosterone, estrogen) levels. Clinically, it is commonly used in acetate or pamoate form, with sustained-release formulations (such as 1, 3, or 6-month injections) to achieve continuous action.
Therapeutic Areas
Oncology
- Prostate cancer: First-line endocrine therapy for advanced, metastatic, or locally high-risk prostate cancer, inhibiting tumor growth by lowering testosterone to castration levels.
- Breast cancer: Used for ovarian function suppression in premenopausal hormone receptor-positive breast cancer, in combination with other drugs to lower estrogen levels.
Gynecology & Reproductive Medicine
- Endometriosis: Relieves pain and inhibits lesion progression.
- Uterine fibroids: Preoperative reduction of fibroid size can decrease surgical difficulty and bleeding.
- Central precocious puberty: Inhibits premature puberty development and improves adult height prognosis.
- Assisted reproductive technology (ART): Used for pituitary downregulation before controlled ovarian hyperstimulation (COS).
Other Fields
- Sex-changing hormone therapy: As an initial treatment in male-to-female transformation, suppressing testosterone secretion.
- Benign prostatic hyperplasia (BPH): Used for temporary relief of severe symptoms (bone health risks should be weighed for long-term use).
Outlook & Development
Market and Clinical Needs
The continued rise in the incidence of prostate and breast cancer, along with the demand for precision medicine in reproductive health, supports long-term market growth. Long-acting formulations (such as 6-month injections) improve patient compliance and represent the current mainstream development direction.
Innovative Formulation and Delivery Systems
Sustained-release technologies such as microspheres and implants extend the dosing interval and reduce injection site adverse reactions. Combination therapies with novel endocrine drugs (e.g., androgen receptor antagonists) or targeted agents aim to enhance anti-tumor efficacy.
Expanding Indications and Individualized Treatment
Ongoing research explores potential applications in ovarian cancer and other pituitary hormone-related disorders. Biomarkers and genetic testing help screen individuals who will derive specific health benefits to optimize personalized treatment strategies.
Generic Drugs and Cost Control
Post-patent competition from generic manufacturers intensifies, driving down healthcare system costs and improving global accessibility, particularly increasing market penetration in emerging regions like Asia and Latin America.
Challenges and Strategic Responses
Managing side effects such as decreased bone density, hot flashes, and cardiovascular risks requires enhanced monitoring and mitigation strategies (such as combined osteoprotective agents). Addressing drug resistance in prostate cancer progression to CRPC necessitates continuous research into sequential or combination regimens.
Conclusion
Triptorelin, a classic GnRH agonist, holds a solid position in oncology and reproductive endocrine disorders. Future development, through dosage form optimization, combination therapies, and expanded indications, is expected to further enhance its clinical value. Meanwhile, the widespread availability of generic versions will promote its rational use globally. Research and development will focus on balancing efficacy and long-term safety, and addressing unmet needs such as drug resistance.
Frequently Asked Questions (FAQ)
What is Triptorelin and how does it work?
Triptorelin is a synthetic decapeptide gonadotropin-releasing hormone (GnRH) agonist. It acts continuously on pituitary GnRH receptors to suppress LH and FSH secretion, effectively reducing sex hormone (testosterone and estrogen) levels in the body.
What oncology conditions can Triptorelin treat?
It is primarily used as a first-line endocrine therapy for advanced, metastatic, or locally high-risk prostate cancer, and for ovarian function suppression in premenopausal hormone receptor-positive breast cancer.
How is Triptorelin applied in gynecology and reproductive medicine?
In gynecology, it helps relieve pain from endometriosis, reduces uterine fibroid size prior to surgery, treats central precocious puberty, and aids pituitary downregulation in assisted reproductive technology (ART).
What are the main delivery options for Triptorelin?
Triptorelin is typically administered via sustained-release depot injections (such as 1, 3, or 6-month formulations) utilizing microsphere or implant technology to maintain consistent therapeutic levels and improve patient compliance.
What side effects or challenges are associated with long-term Triptorelin use?
Long-term suppression of sex hormones can lead to side effects such as decreased bone mineral density, hot flashes, and cardiovascular risks. Management strategies include regular monitoring, co-administration of osteoprotective agents, and evaluating therapy changes if drug resistance develops.
